Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III BI 456906 vs placebo in Japanese adults with obesity
jRCT2031230522Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing BI 456906 with Placebo (2 arms). Primary endpoints: Percentage change in body weight from baseline to Week 76 and Achievement of body weight reduction ≥5% from baseline to Week 76. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT2031230522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230522.